Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, talks about the pooled analysis of the efficacy of defibrotide in adults with veno-occlusive disease (VOD). Defibrotide has shown striking efficacy in pediatric patients with VOD, while showing a consistent safety profile; therefore, the treatment may be introduced at an earlier stage as a preventative measure in pediatric patients and in part for adults. Dr Richardson also touches upon the research concerning thrombotic microangiopathy, and other studies being planned to reduce graft-versus-host disease in transplant patients.
Endothelial dysfunction in transplant: defibrotide for VOD
